Restoring tumor suppression via precision microvesicle delivery of p53 mRNA

A non-viral, immune-silent platform delivering next-generation gene therapy directly to cancer cells.

Mission & Overview

Our mission is to transform oncology through precision-engineered microvesicles that deliver p53 mRNA directly to cancer cells. By utilizing a non-viral, immune-silent delivery platform, we bypass the limitations of traditional gene therapy to restore tumor suppression in advanced solid tumors.

Our Lead Candidate: ecm-RV/p53

  • Genetically engineered cellular microvesicle (ecm) and non-viral RNA vesicle (RV)
  • Loaded with our proprietary, in vitro transcribed p53 mRNA

Platform Technology

  • Precision-engineered microvesicle architecture
  • Ability to carry multiple types of payloads to power future pipeline expansions or partnerships